BiomX Inc. Stock: price and insider trades · United States

BiomX Inc. is a United States-listed company trading on the NYSE American market under the ticker PHGE, and it has historically been best known as a phage- and microbiome-focused biotechnology company. For investors in France, Belgium, and Switzerland, it fits the profile of a small-cap, high-risk biotech with meaningful clinical, regulatory, and financing risk. The company was founded out of the FutuRx incubator with support from the Israel Innovation Authority, and it built its original platform around the discovery and development of therapies targeting specific pathogenic bacteria. Its operating roots are in Israel, with a historical headquarters in Ness Ziona.

BiomX’s core business, in its original form and still reflected in its public communications, centers on developing natural and engineered phage cocktails designed to treat diseases driven by specific bacterial targets. The company has disclosed programs across acne, inflammatory bowel disease, oncology-related applications, and microbiome modulation approaches. This is the classic structure of an advanced-stage platform biotech: value creation depends on scientific differentiation, intellectual-property protection, clinical execution, and the ability to fund development long enough to generate meaningful readouts.